SCHEMBL3816144

SCHEMBL3816144

CC(C)(C)OC(=O)NCCNc1nc(NC(=O)C(F)(F)F)ccc1N

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LATS1 O95835 2/20 0.47
BCHE P06276 1/20 0.43
BRD4 O60885 7/20 0.42
STK17B O94768 1/20 0.40
STK17A Q9UEE5 1/20 0.40
MALT1 Q9UDY8 1/20 0.39
ADORA3 P0DMS8 1/20 0.38
ADORA2A P29274 1/20 0.38
ADORA1 P30542 1/20 0.38
CA12 O43570 2/20 0.38
CA1 P00915 2/20 0.38
CA2 P00918 2/20 0.38
CA9 Q16790 2/20 0.38
OPRM1 P35372 1/20 0.36
OPRD1 P41143 1/20 0.36
OPRK1 P41145 1/20 0.36
OGFRL1 Q5TC84 1/20 0.36
SUV39H2 Q9H5I1 1/20 0.36
PDE3B Q13370 1/20 0.36
PDE3A Q14432 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3815554 0.83 LATS1 (0.42) LATS1BCHEBRD4STK17BSTK17A
SCHEMBL3816138 0.80 GBA1 (0.34) ADORA3OPRK1
SCHEMBL3408155 0.78 LATS1 (0.48) LATS1BCHEBRD4STK17BSTK17A
SCHEMBL8003136 0.76 BCHE (0.44) LATS1BCHEBRD4STK17BSTK17A
SCHEMBL4069369 0.75 CA14 (0.33)
SCHEMBL1513970 0.74 BCHE (0.43) LATS1BCHEBRD4STK17BSTK17A
SCHEMBL4269455 0.73 LATS1 (0.50) LATS1BCHEBRD4STK17BSTK17A
SCHEMBL3407489 0.72 STK17B (0.53) BRD4STK17BSTK17AADORA2AADORA1
SCHEMBL1513971 0.70 BCHE (0.46) LATS1BCHEBRD4STK17BSTK17A
SCHEMBL24640570 0.70 ALDH1A1 (0.46) LATS1BCHEBRD4STK17BSTK17A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1615925-B1 IMIDAZOPYRIDINE DERIVATIVES AS MELANOCORTIN RECEPTOR AGONISTS IPSEN PHARMA (FR) 2009-05-27 EP disclosed
US-7495009-B2 Imidazopyridine derivatives as melancortin receptor agonists SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) 2009-02-24 US disclosed
US-20060173036-A1 Imidazopyridine derivatives as melanocortin receptor agonists SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S) (FR) 2006-08-03 US disclosed
EP-1615925-A1 IMIDAZOPYRIDINE DERIVATIVES AS MELANOCORTIN RECEPTOR AGONISTS Société de Conseils de Recherches et d'Applications Scientifiques ( S.C.R.A.S.) (FR) 2006-01-18 EP disclosed
WO-2004089951-A1 IMIDAZOPYRIDINE DERIVATIVES HAVING AN AFFINITY FOR MELANOCORTIN RECEPTORS SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) 2004-10-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060173036-A1 Imidazopyridine derivatives as melanocortin receptor agonists MC4R, MC1R, MC3R LATS1 3321/4885BCHE 4411/4885BRD4 256/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.